Empro Group Inc. Ordinary shares (EMPG)vsMerck & Company Inc (MRK)
EMPG
Empro Group Inc. Ordinary shares
$17.36
0.00%
HEALTHCARE · Cap: $143.05M
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1199018% more annual revenue ($65.77B vs $5.48M). EMPG leads profitability with a 13.7% profit margin vs 13.6%. MRK trades at a lower P/E of 32.6x. MRK earns a higher WallStSmart Score of 50/100 (D+).
EMPG
Hold47
out of 100
Grade: D+
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EMPG.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 49 in profit
Strong operational efficiency at 36.1%
Revenue surging 141.6% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Trading at 17.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EMPG
The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : EMPG
The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
EMPG profiles as a growth stock while MRK is a value play — different risk/reward profiles.
EMPG is growing revenue faster at 141.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 47/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Empro Group Inc. Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?